The aim of this study was to investigate the effects of topotecan (Hycamtin), a topoisomerase I inhibiting anticancer agent, on antioxidant enzymes (SOD, CAT, and GSH-Px) and TBA-RS values of the submandibular glands of the rabbits.
STUDY DESIGN AND SETTING:
The study was conveyed in two groups (Group I, II) and control with a total of 24 rabbits. Eight rabbits in group I received intravenous (i.v.) topotecan (0.25 mg/kg once daily) for 3 days. Eight rabbits in group II received i.v. topotecan (0.5 mg/kg once daily) for 3 days. On the 15th day after administration of topotecan, sub-mandibular glands were removed and levels of the SOD, CAT, and GSH-Px and the TBA-RS in the sub-mandibular glands of the rabbits were examined.
RESULTS:
SOD, CAT, and GSH-Px values were significantly higher in high-dose topotecan group compared to control group (P < 0.05). SOD and TBA-RS values were significantly higher in high-dose topotecan group compared to low-dose topotecan group (P < 0.05).
CONCLUSION:
It was concluded that, to prevent the hazardous effects of oxygen free radicals due to topotecan, antioxidant enzymes SOD, CAT, and GSH-Px were increased. The higher levels of the TBA-RS values in group II showed that permanent damage was present because of high-dose topotecan administration in the submandibular glands of the rabbits.
Get full access to this article
View all access options for this article.
References
1.
. ParksRRHuangCCHaddadJ.Jr Middle ear catalase distribution in an animal model of otitis media. Eur Arch Otorhinolaryngol1996;253:445–9.
2.
. SouthornPAPowisG.Free radicals in medicine. II. Involvement in human disease. Mayo Clin Proc1988; 63: 390–408.
3.
. MonteMDe SacerdoteLE.Free radicals of oxygen and superoxide dismutase. Biological and medical aspects. Medicina (B Aires)1994;54(1):61–8.
4.
. ZuninoFPratesiGMicheloniA, Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact1989;70(1):89–101.
5.
. OberleyLWBuettnerGR.Role of superoxide dismutase in cancer: a review. Cancer Res1979;39:1141–9.
6.
. PowisG.Anthracycline metabolism and free radical formation. In: PowisGProughR, editors. Metabolism and Action of Anti-Cancer Drugs. London: Taylor and Francis; 1987. p. 211–60.
7.
. TakimotoCHArbuckSG.Clinical status and optimal use of topotecan. Oncology (Huntingt)1997 Nov;11(11):1635–46, 1649–51, 1655–7.
8.
. RovinskyEKGrochowLBHendricksCB, Phase I and pharmacologic study of Topotecan: A novel Topoisomerase I inhibitor. J Clin Oncol1992;10(4):647–56.
9.
. KantarjianHMBeranMEllisA, Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood1993 March;81(5):1146–51.
10.
. KrautEHCrowleyJWadeJL, Evaluation of topotecan in resistant and relapsing multiple myeloma: A Southwest Oncology Group study. J Clin Oncol1998 February;16(2):589–92.
11.
. AebiH. Catalase In: BergmeyerHU, editor. Methods of enzymatic analysis. New York: Academic Press; 1974. p. 673–7.
12.
. durakICanbolatOKavutçuM, Activities of total, cytoplasmic and mitochondrial superoxide dismutase enzymes in sera and pleural fluids from patients with lung cancer. J Clin Lab Anal1996;10:17–20.
13.
. PagliaDEValentineWN.Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med1967;70:158–69.
14.
. Van YeTMRozaAMPieperGM, Inhibition of intestinal lipilipid peroxidation does not minimize morphological damage. J Surg Res1993;55:553–8.
15.
. LowryORosenbroughNFarrL, Protein measurement with the folin phenol reagent. J Biol Chem1951;183:265–75.
16.
. FujitaIIOkatomaMTakaoA, Pharmacokinetics of SK & F 104 864 in experimental animals I, Plasma level. Gan To Kogaku Ryoho1995 Oct;22(12):1783–7.
17.
. StraathofCSVan Den BentMJLoosWJ, The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration. J Neurooncol1999 Apr;42(2):117–22.
18.
. SmithRELewDRodriguezGI, Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study. Invest New Drugs1996;14(4):403–7.
19.
. RobertFSoongsSJWheelerRH.A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent. Am J Clin Oncol1997 Jun;20(3):298–302.
20.
. AsburyRFLipsitzSGrahamD, Treatment of squamous cell esophageal cancer with topotecan: an Eastern Cooperative Oncology Group study (E2293). Am J Clin Oncol2000 Feb;23(1):45–6.
21.
. CersosimoRJ.Topotecan: A new Topoisomerase I inhibiting antineoplastic agent. Ann Pharmacother1998 December;32:1334–43.
22.
. ChenKLichtensteinSVWalleyKR.Potential deleterious effect of beta adrenergic stimulation during warm-blood cardioplegia in rabbit hearts. J Invest Surg2001 Jul-Aug;14(4):213–20.
23.
. 52nd WMA General Assembly. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA2000; 284: 3043–9.
24.
. RybakLPWhitworthCSomaniS.Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope1999;109:1740–4.
25.
. ClericiWJDimartinoDLPrasadMR.Direct effects of reactive oxygen species on cochlear outer hair cell shape in vitro. Hear Res1995;84:30–40.
26.
. RybakLPHusainKEvensonL, Protection by 4-methylthiobenzoic acid against cisplatin-induced ototoxicity: Antioxidant system. Pharmacol Toxicol1997;81:173–9.
27.
. HeronJF.Topotecan: An oncologist's view. Oncologist1998;3(6):390–402.
28.
. CharcossetJYSouesSLavalF.Poisons of DNA topoisomerases I and II. Bull Cancer1993;80(11):923–54.
29.
. koltuksuzUOzenSAydinçM, Plasma superoxide dismutase activity and malondialdehyde level correlate with the extent of acute appendicitis. Pediatr Surg Int2000;16:559–61.
30.
. akkuşISaclamNICaclayanO, Investigation of the erythrocyte membrane lipid peroxidation and antioxidant defense system of patients with coronary artery disease (CAD) documented by angiography. Clin Chim Acta1996;244:173–80.
31.
. GuemouriLArturYHerbethB.Biological variability of superoxide dismutase, glutathione peroxidase and catalase in blood. Clin Chem1991;37:1932–7.
. CarbonneauMAPeuchantESessD, Free and bound malondialdehyde measured as thiobarbituric acid adduct by HPLC in serum and plasma. Clin Chem1991;38(8):1423–9.
34.
. ChangAR.An analysis of the pathology of 3003 appendices. Aust N Z J Surg1981;51:169–78.
35.
. MclordJMFridovichI.Superoxide dismutase: an enzymatic function for erythrocuprein (hemocuprein). J Biol Chem1969;6049–55.
36.
. SlaterTFCheesemanKHDaviesMJ, Free radical mechanism in relation to tissue injury. Proc Nutr Soc1987;46(1):1–12.
37.
. DennisKJShibamatoT.Gas chromatographic determination of malondialdehyde formed by lipid peroxidation. Free Rad Biol Med1989;7:187–92.
38.
. DraperHHHadleyM.A review of recent studies on the metabolism of exogenous and endogenous malondialdehyde. Xenobiotica1990;20:901–7.
39.
. TatumVLChangchitCChowCK.Measurement of malondialdehyde by high performance liquid chromatography with fluorescence detection. Lipids1990;25:226–9.
40.
. DianzaniMU.Lipid peroxidation and cancer: a critical reconsideration. Tumori1989;75:351–7.
41.
. DormandyTL.Vitamin E and antioxidant activity. Proc R Soc Med1977;70:91–3.
